Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Gains from Investment Securities (2020 - 2023)

Historic Gains from Investment Securities for Relay Therapeutics (RLAY) over the last 4 years, with Q4 2023 value amounting to $12.4 million.

  • Relay Therapeutics' Gains from Investment Securities changed N/A to $12.4 million in Q4 2023 from the same period last year, while for Sep 2025 it was $25.8 million, marking a year-over-year change of. This contributed to the annual value of $101000.0 for FY2024, which is 9918.49% down from last year.
  • As of Q4 2023, Relay Therapeutics' Gains from Investment Securities stood at $12.4 million.
  • Relay Therapeutics' Gains from Investment Securities' 5-year high stood at $30.4 million during Q4 2021, with a 5-year trough of -$4.6 million in Q1 2022.
  • For the 4-year period, Relay Therapeutics' Gains from Investment Securities averaged around $7.2 million, with its median value being $1.5 million (2023).
  • As far as peak fluctuations go, Relay Therapeutics' Gains from Investment Securities surged by 29495.61% in 2021, and later surged by 13292.32% in 2023.
  • Quarter analysis of 4 years shows Relay Therapeutics' Gains from Investment Securities stood at $7.7 million in 2020, then skyrocketed by 294.96% to $30.4 million in 2021, then tumbled by 115.12% to -$4.6 million in 2022, then soared by 369.68% to $12.4 million in 2023.
  • Its Gains from Investment Securities was $12.4 million in Q4 2023, compared to $1.5 million in Q3 2023 and $1.5 million in Q2 2023.